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24 The Journal of Thoracic and Cardiobjective(s): Even though the mechanism is not clearly understood, direct intramyo-
ardial cell transplantation has demonstrated potential to treat patients with severe
eart failure. We previously reported on the bioengineering of myoblast-based
onstructs. We investigate here the functional outcome of infarcted hearts treated by
mplantation of myoblast-seeded scaffolds.
ethods: Adult Lewis rats with echocardiography-confirmed postinfarction reduced
jection fraction (48.3% 1.1%) were randomized to (1) implantation of myoblast-
eeded polyurethane patches at the site of infarction (PU-MyoB, n  11), (2)
mplantation of nonseeded polyurethane patches (PU, n  11), (3) sham operation
Sham, n  12), and (4) direct intramyocardial myoblast injection (MyoB, n  11).
our weeks later, the functional assessment by echocardiography was repeated,
nd we additionally performed left ventricular catheterization plus histologic
tudies.
esults: The ejection fraction significantly decreased in the PU (39.1%  2.3%; P
.02) and Sham (39.9%  3.5%; P  .04) groups, whereas it remained stable in
he PU-MyoB (48.4%  3.1%) and MyoB (47.9%  3.0%) groups during the
bservation time. Similarly, left ventricular contractility was significantly higher in
roups PU-MyoB (4960  266 mm Hg/s) and MyoB (4748  304 mm Hg/s) than
n groups PU (3909  248 mm Hg/s, P  .01) and Sham (4028  199 mm Hg/s,
 .01). Immunohistology identified a high density of myoblasts within the seeded
caffolds without any migration toward the host cardiac tissue and no evidence of
ardiac cell differentiation.
onclusions: Myoblast-seeded polyurethane scaffolds prevent post–myocardial in-
arction progression toward heart failure as efficiently as direct intramyocardial
njection. The immunohistologic analysis suggests that an indirect mechanism,
otentially a paracrine effect, may be assumed.
nimal studies have recently shown that intramyocardial injection of sk
myoblasts can prevent the progressive hemodynamic alterations after a
myocardial infarction (MI).1–3 These results, as well as the preliminary 
rom clinical phase I studies,4–6  are encouraging in a field where no treatm
xcept organ transplantation has clearly demonstrated its efficacy. However, the
yocardial injection process is associated with a dramatically high rate of imme-
iate cell death that may potentially limit the benefits of this technique.7–9 One
ossible approach for overcoming this hurdle could be to use biodegradable scaf-
olds seeded with the candidate cell. We10 recently reported on the process 
ptimally seeding myoblasts on Artelon polyurethane (PU) scaffolds (Artimplant
B, Västra Frölunda, Sweden). In the current work, we have evaluated the possible
unctional benefit of these bioengineered constructs in a rat model of ischemic heart
ailure and compared this new approach with direct intramyocardial injection.
vascular Surgery ● July 2006
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TXethods
yoblast Culture
keletal myoblasts were isolated and expanded from male new-
orn Lewis rats as described previously.11 In brief, limb muscle
ere minced and enzymatically dissociated with 1.5 mg/mL col-
agenase IA (Sigma Chemical Company, St Louis, Mo) and 0.25%
rypsine–ethylenediaminetetraacetic acid (Gibco, Auckland, New
ealand). After passage through 100- and 40-m filters (Falcon;
D, Franklin Lakes, NJ), cells were expanded in culture medium
onsisting of 57% minimum Eagle medium (Gibco), 27% M199
Gibco), 15% fetal bovine serum (HyClone, Logan, Utah), 1% P/S
Gibco), and 5 ng/mL beta fibroblast growth factor (Sigma). We
arvested the cells by trypsinization after 48 hours, counted them,
nd froze them in culture medium containing 10% dimethyl sul-
oxide (Sigma). An average of 14.4  2.2  106 cells were
btained per newborn Lewis rat. The proportion of skeletal myo-
lasts was estimated by anti-desmin (Monoclonal Anti Desmin,
lone DE-U-10; Sigma) immunolabeling as described previousl12
ulture purity reached 33.2%  1.9% of desmin-positive myo-
lasts. Cells were later thawed, diluted, centrifuged, and counted
efore being seeded on PU scaffolds.
caffold Preparation
he manufacturing of Artelon PU scaffolds was described previ-
usly.13 In brief, Artelon is a long-term degradable biomate
hich degrades by hydrolysis over a period of approximately 5
ears. In this study, the biomaterial was processed into a highly
orous scaffold (90%  3% volume porosity) with interconnected
ores.
We prepared the scaffolds in groups of three: one seeded
caffold for implantation, one seeded scaffold for cell count and
iability validation, and one unseeded scaffold. These unseeded
caffolds were incubated for 14 days in culture medium to obtain
imilar physical properties as compared with the implanted
aterial.
For cell seeding, 7.5  7.5  2.0-mm scaffolds were coated
ith 10 g/mL laminin (Invitrogen, Carlsbad, Calif) before 4.9 
.2  106 cells were pipetted (30-L suspension) over their
urface. After a 30-minute attachment time, the seeded scaffolds
Abbreviations and Acronyms
dP/dtmax  left ventricular contractility
dP/dtmin  left ventricular relaxation
EF  ejection fraction
LVEDP  left ventricular end-diastolic pressure
LVESP  left ventricular end-systolic pressure
LVEDV  left ventricular end-diastolic volume
LVESV  left ventricular end-systolic volume
MI myocardial infarction
PU  polyurethane
PU-MyoBmyoblast-seeded polyurethane patches at
the site of infarction
PU  nonseeded polyurethane patches
MyoB  direct intramyocardial myoblast injectionere placed on silicone-coated dishes (Sylgard 184; Truller, Fu- v
The Journal of Thoracicenbach, Switzerland) in 2-mL culture medium and incubated at
7°C for 14 days with medium changes every 60 hours. Our
urrent seeding protocol was adopted after a previous systematic
nalysis of several seeding conditions was performed.10 In this
reliminary study, spectrometic MTT viability test (MTT thiazolyl
lue; Sigma), CyQuant Cell Proliferation Assay Kit (Molecular
robes, Eugene, Ore), and immunohistology were used to assess
ell viability and cell number.
nimal Model
he animals received human care in compliance with the “Princi-
les of Laboratory Animal Care” formulated by the National
ociety for Medical Research and the “Guide for the Care and Use
f Laboratory Animals” prepared by the Institute of Laboratory
nimal Resources and published by the National Institutes of
ealth (NIH Publication No. 86-23, revised 1985). All procedures
ere performed in accordance with the Swiss Animal Protection
aw after obtaining the permission of the State Veterinary Office,
ern, Switzerland.
For the operative procedures, female Lewis rats (average
eight: 203  1 g) were anesthetized with isoflurane (5% of
xygen for induction and 2.5% of oxygen for maintenance) and
dditive buprenorphine (10 g/kg), placed on a warming pad
37°C), and tracheally ventilated at 80 cycles/min (14-gauge in-
ravenous cannula, Abbocath; Abbott, Sligo, Republic of Ireland;
mall Animal Ventilator 683; Harvard Apparatus Inc, Holliston,
ass).
On day 0, an MI was induced through a left lateral thoracotomy
y ligation of the left anterior descending coronary artery with a
-0 polypropylene suture (Ethicon, Inc, Somerville, NJ). On day
4, a baseline echocardiographic analysis was performed before
he animals were randomized to receive either a sham operation
group Sham  sternotomy and adhesiolysis only, n  11), the
mplantation of a myoblast-seeded (PU-MyoB, n  11) or non-
eeded scaffold (PU, n  12), or the direct intramyocardial injec-
ion of a myoblast suspension (MyoB, n  11), or medium only
Medium, n  10). All interventions were performed through a
edian sternotomy. The scaffolds were attached to the outer
urface of the myocardial scar with 4 single-knot sutures connect-
ng the PU scaffold edges with the infarction area edges. In the
yoB group of animals, 4.8  0.9  106 cells in 150-L medium
containing 15% fetal bovine serum) were distributed within the
car via 4 to 6 intramyocardial injection sites. Four weeks after the
ntervention (day 42), the rats were anesthetized for echocardiog-
aphy and left ventricular pressure measurements before the hearts
ere explanted for histologic analysis.
We additionally included a supporting group of 7 normal
ge-matched rats without MI or other intervention to serve as
eferences for the echocardiographic values.
unctional Assessment by Echocardiography
he echocardiographic analyses were performed in a blinded man-
er with a 9 to 11-MHz linear array transducer system (Acuson
equoia; Siemens Inc, Malvern, Pa). Animals were anesthetized
ith 2.5% isoflurane by mask and placed on the left lateral
osition. The ejection fraction (EF) was calculated as described
reviously.12 In brief, in a 2-dimensional long-axis view, the
entricular end-diastolic (LVEDV) and end-systolic volumes
and Cardiovascular Surgery ● Volume 132, Number 1 125
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1
TXLVESV) were calculated by the single-plane area (A)  length
L) method: Volume  8  A2/(3    L). The EF was then
alculated as: EF  (LVEDV  LVESV)/LVEDV. Heart rate was
easured in a short-axis view.
ostinterventional Catheterization
he analysis was also performed in a blinded manner. The tip of
1.4F pressure catheter (Millar Mikro-Tip; Millar Instruments,
nc, Houston, Tex) was placed via the right carotid artery into the
eft ventricle before the animals were positioned in the left lateral
osition.14 After a stabilization period of 5 minutes, the pres
urves of 10 to 15 subsequent arbitrarily chosen beats were re-
orded and used to calculate the left ventricular contractility (dP/
tmax), relaxation (dP/dtmin), end-systolic pressure (LVESP), end-
iastolic pressure (LVEDP), and heart rate.
istology
he hearts were cut in 3-mm-thick slices orthogonal to the long
xis of the heart axis before being frozen in O.C.T. compound
Tissue Tek, Sakura Finetek, Zoeterwoude, Netherlands) and
tored at 80°C. We then prepared 5-m-thick cryosections on
lides fixed with paraformaldehyde and stained with hematoxylin
nd eosin or an immunostain. For the latter, the slides were
locked with 3% bovine serum albumin (Sigma), then incubated
0 minutes with either of the following primary antibodies: anti-
esmin (ready to use, Mouse Anti-Human Desmin MCA849HT;
erotec, Oxford, United Kingdom), anti--actinin (sarcomeric)
1:800, Clone EA-53; Sigma), anti-skeletal myosin (fast) (1:400,
lone MY-32; Sigma), and anti-skeletal myosin (slow)
MAB1628, 1:400; Chemicon International, Temecula, Calif).
hereafter, the slides were incubated for 30 minutes with a horseradish-
eroxidase–linked secondary antibody (1:50 F(ab=)2 Rabbit Anti
ouse immunoglobulin G [AFF.PUR]:HRP, STAR 13B; Sero-
ec). Coloration steps with AEC (A6926; Sigma) application and
ematoxylin were then performed.
tatistics
ata were analyzed by a computerized statistical program (Sig-
aStat; SPSS Inc, Chicago, Ill). The results are expressed as mean
SE. One-way analysis of variance was used to compare treat-
ent groups. If significant differences were detected, pair-wise
ultiple comparison procedures were then performed (Holm-
ABLE 1. Animal statistics
No MI Sham
eath post intervention 2
eath at pressure catheter 1
xclusion — —
ncluded number of
animals
7 12
o MI, normal rats without myocardial infarction; Sham, sham operation; P
olyurethane patch; Medium, contrast medium only; death post interventio
arotid artery ruptured, the catheter did not pass the aortic valve, or the a
f the sternotomy wound with intrathoracic involvement.idak method). A paired t test was used to test the differences c
26 The Journal of Thoracic and Cardiovascular Surgery ● Julyetween preinterventional and postinterventional parameters. A 2
est was used to analyze the mortality rate.
esults
reimplantation Seeded Scaffold Assessment
ix hours after cell seeding, the CyQuant proliferation assay
howed that 34.9%  5.0% of delivered cells (5  106)
ere attached to the PU scaffold. After an incubation time
f 14 days, cell count increased and peaked to 80.9% 
.2% of the initially delivered cells (P  .001 vs 6 hours
fter seeding). Similarly, viability after 14 days’ incubation
ncreased by 29.8%  2.5% as compared with 6 hours after
eeding as assessed by MTT test (P  .001). Purity of
yoblasts in culture was unaffected during this incubation
ime.
ortality and Morbidity
f a total of 113 surgically treated animals, 62 could be
ncluded in this study (54.9%). Twenty-eight rats (24.7%)
ied immediately after MI of ventricular arrhythmia; 2 rats
1.7%) died between the MI and the first echocardiographic
tudy. We further excluded 15 animals (13.3%) on the basis
f an echocardiographic EF smaller than 30% (3 rats) or
reater than 60% (12 rats). Three animals (2.6%) died of
leeding during the intervention procedure. Two animals
ied on days 2 and 5 after the intervention in severe heart
ailure. Five animals that were included in the study died
uring the postinterventional catheterization (Table 1). 
hese 5 animals, 4 died of fatal arrhythmia during catheter
lacement and 1 died of bleeding. Importantly, none of
hose last 7 animals dying after the intervention belonged to
ither the MyoB or the PU-MyoB groups, making the mor-
ality rate of non–myoblast treated animals 20.0% (7/35) as
ompared with 0% (P .05) in the myoblast-treated groups
f animals. Finally, 1 PU-MyoB rat was excluded from the
tudy owing to an extended intrathoracic wound infection.
chocardiographic Data
n normal rats without MI (group no MI), EF was signifi-
PU-MyoB MyoB Medium Total
— — — 2
— — 2 5
1 — — 1
11 11 10 62
plantation of nonseeded polyurethane patch; PU-MyoB, myoblast-seeded
mals died 2 and 5 days after intervention; Death at pressure catheter, the
ls died of arrhythmia; Exclusion, the rat had dehiscent and deep infectionPU
—
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TXower than in all groups of animals with MI and consecutive
ntervention (P  .001). The heart rate and body weight did
ot differ between rats with no MI and the randomized rats.
The preinterventional echocardiographic evaluation con-
rmed the absence of differences between the randomized
roups regarding ventricular function (EF), ventricular sizes
LVESV, LVEDV), or heart rate (Table 2).
At the postinterventional echocardiograpic assessment
Table 3), the ventricular function (EF) in the con
roups Sham, PU, and Medium decreased significantly as
ompared with the preinterventional values (P  .021 for
ham, P  .003 for PU, P  .013 for Medium). As
hown in Figure 1, the postinterventional EFs of 
U-MyoB and MyoB animals were significantly higher
han those of the Sham, PU, and Medium groups (PU-
yoB vs Sham, P  .042; PU-MyoB vs PU, P  .034;
yoB vs Medium, P  .017). A slight increase in
VEDV in groups Sham, PU, PU-MyoB, and Medium
id not reach statistical significance as compared with
reinterventional values (Figure 2). Conversely, e
oint LVESV was significantly higher in the PU (P 
021) and Medium (P  .018) groups compared with
ABLE 2. Preinterventional hemodynamic data (echocardi
No MI (n  7) Sham (n  12) PU (n  1
F 72.9  3.5* 48.2 2.7 48.3  2.1
VEDV 0.294 0.032* 0.441 0.042 0.400  0.0
VESV 0.092 0.010* 0.233 0.028 0.210  0.0
R 386  11 387 15 384  12
W 214  4 214 3 215  3
o MI, Normal rats without myocardial infarction; Sham, sham operation; P
olyurethane patch; Medium, contrast medium only; EF, ejection fraction
nd-systolic volume (mL); HR, heart rate (1/min); BW, body weight (g). Val
ABLE 3. Postinterventional hemodynamic data (echocard
Sham (n  12) PU (n  11)
F 40.1 2.8* 39.6  1.8*
VEDV 0.542 0.053 0.519 0.050
VESV 0.328 0.047 0.312 0.030*
R (echo) 358 5 368  8
W 234  3* 230  4*
P/dtmax 4027 199 3908  248
P/dtmin 3964 205 3661 258
VESP 113  3 110  5
VEDP 13.3 4.0 13.9  4.0
R (cath) 335 10 328  9
o MI, Normal rats without myocardial infarction; Sham, sham operation; P
olyurethane patch; Medium, contrast medium only; EF, ejection fraction
nd-systolic volume (mL); HR (echo), heart rate measured echocardiograp
g/s); dP/dtmin, left ventricular relaxation (mm Hg/s); LVESP, left ventricula
mm Hg); HR (cath), heart rate measured with pressure-tip catheter (1/min
05 versus PU; §P  .05 versus Medium.
The Journal of Thoracicreinterventional values, but without differences between
he groups (Figure 3). The heart rate at the tim
chocardiographic assessment was similar in all groups,
nd the body weight was significantly higher than prein-
erventional values in all groups.
atheterization
he left ventricular contractility (dP/dtmax) and relaxation (dP/
tmin) were significantly better in the PU-MyoB group of
nimals than in sham-operated animals (P .010 for contrac-
ility and P  .049 for relaxation) and PU animals (P  .006
nd P  .011, respectively). Similarly, the MyoB group of
nimals had higher contractility and relaxation values as com-
ared with the PU group (P  .026 for contractility and P 
015 for relaxation). The values for the control group Medium
id not significantly differ from those seen in the myoblast
reatment groups or in the other control groups (Figure 
istology
efore transplantation, cell viability (95%) and anti-
esmin positivity rate (33.2  1.9) were not affected by the
reezing/thawing process.
phy)
PU-MyoB (n  11) MyoB (n  11) Medium (n  10)
47.9 2.1 47.4 3.0 50.1 2.1
0.416 0.024 0.437 0.044 0.372 0.0212
0.222 0.022 0.251 0.035 0.185 0.011
360 8 369 14 370 8
220 2 217 3 216 2
plantation of nonseeded polyurethane patch; PU-MyoB, myoblast-seeded
LVEDV, left ventricular end-diastolic volume (mL); LVESV, left ventricular
re mean  SE. *P  .001 versus all groups before and after intervention.
phy and left ventricular catheterization)
U-MyoB (n  11) MyoB (n  11) Medium (n  10)
48.4 3.1†‡§ 47.9 3.0†‡§ 40.1 4.1*
0.492 0.038 0.438 0.019 0.429 0.023
0.251 0.026 0.230 0.019 0.246 0.019*
355  5 355  11 357 8
235  4* 234 3* 236 2*
4960 266†‡ 4748 304†‡ 4401 229
4751 319†‡ -4705 354‡ 4227 286
123  5 126  7 115 6
13.4  2.2 10.2 1.5 7.9 1.2
340  7 334  8 317 9
plantation of nonseeded polyurethane patch; PU-MyoB, myoblast-seeded
LVEDV, left ventricular end-diastolic volume (mL); LVESV, left ventricular
y (1/min); BW, body weight (g); dP/dtmax, left ventricular contractility (mm
-systolic pressure (mm Hg); LVEDP, left ventricular end-diastolic pressure
lues are mean  SE. *P  .05 versus pre; †P  .05 versus Sham; ‡P ogra
1)
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1
TXIn all animals the MI was confirmed by hematoxylin-
osin staining. Additionally, immunostaining with anti--
ctinin and anti-slow-muscle myosin demonstrated viable
yocardium surrounding the infarction zone (Figure 5b
nd c).
In the animals injected with skeletal myoblasts, a differ-
ntiation of the engrafted cells to myotubes was evidenced
y a positive staining for anti-skeletal myosin (fast), which
as distributed regularly within the infarction zone (Fig
, d).
igure 1. Left ventricular ejection fraction (LVEF [%]). Gray bar,
o MI, healthy animals without myocardial infarction; Sham,
nimals with infarction but without intervention; PU, nonseeded
olyurethane scaffold implantation; PU-MyoB, scaffolds seeded
ith myoblasts; MyoB Inj, direct intramyocardial injection; Me-
ium, medium injection. *P < .05 versus preintervention in the
ame group; #P < .05 versus Sham; §P < .05 versus PU; $P < .05
ersus Medium; †P < .05 versus all groups preinterventional and
ostinterventional.
igure 2. Left ventricular end-diastolic volume (LVEDV) in percent
f the preinterventional values. For abbreviations, see Figure 1. #
28 The Journal of Thoracic and Cardiovascular Surgery ● JulyMacroscopically, the scaffolds in the PU-MyoB and PU
roups were not degraded and were strongly sticking to the
nfarcted surface. Neo-vessels could be noticed within the
dhesion tissue surrounding the scaffold (Figure 5, a). His-
ologic analysis of hematoxylin-eosin–stained sections re-
ealed a dense cellular colonization including vasculariza-
ion of the scaffolds in both groups. The scaffold material
tself showed no histologic signs of degradation. No inflam-
atory reaction of the neighboring host tissue nor encapsu-
ation of the graft was detected .The mononuclear cells were
andomly oriented. We detected neither myotubes (negative
taining for anti-(fast)-skeletal myosin) nor ingrowths of
yocardium (negative staining for anti--actinin and anti-
low-muscle myosin) inside the grafts (Figure 5, e). In th
igure 3. Left ventricular end-systolic volume (LVESV) in percent
f the pre-interventional values. For abbreviations, see Figure 1.
igure 4. Left ventricular contractility (dP/dtmax) and relaxation
dP/dt ). For abbreviations, see Figure 1. *P < .05 versus Sham,min
P < .05 versus PU.
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TXnimals implanted with myoblast-based scaffolds, only
esmin-positive cells were detected in great numbers
hroughout the scaffolds (Figure 5, f). As expected, n
esmin-positive cells were detected in the control non-
eeded scaffolds. Interestingly, 4 weeks after in vivo im-
lantation of the PU MyoB, the desmin-positively stained
ells remained isolated from each other and did not show
ny intracellular striation, suggesting they had retained an
ndifferentiated pattern. In addition, we found no penetra-
ion of these scaffold-bound cells into the neighboring myo-
ardium or infarction zone.
iscussion
his study demonstrates the potential value of approaching
he therapy of ischemic heart failure by engrafting a 
ngineered cell-seeded scaffold. The most salient findi
f this study are as follows: (1) Myoblast-seeded PU 
Figure 5. Macroscopy and immunohistology 4 weeks
scaffold (PU-MyoB group). Note the visible vessels run
myocardium (Sham group) surrounded by viable endo
myosin immunostaining (100). c, Viable myocardium
anti-actinin immunostaining (600). Note the striation
myotubes in the infarction zone (MyoB group) stained b
anti-skeletal myosin (600). Inside the PU scaffold (PU
myosin positivity can be detected suggesting missing
staining using anti-desmin antibodies to visualize the
entiated throughout the scaffold in great numbers (600olds prevent further deterioration of left ventricular func-p
The Journal of Thoracic-
-
ion after MI compared with placebo-injected controls, 
2) they do not yield a better preservation of left ventricular
unction than myoblasts directly injected into the scarred
yocardium; (3) even though the number of animals tested
as small, the implantation of a myoblast-seeded scaffold
fter an MI seemed to reduce the mortality, inasmuch as
one of these animals died during the 4 weeks’ observation
eriod as compared with a mortality rate of 20% observed in
he groups that did not receive myoblasts.
The initial results of phase I clinical trials of skeletal
yoblast transplantation have provided encouraging
ints,4–6  although clear-cut evidence for efficacy is s
acking and will only be provided by randomized studies,
ne of which is already ongoing. However, regardless of the
utative benefits of the procedure, it is likely that its efficacy
till remains limited by the high rate of early posttransplan-
ation cell death7–9 and the inability of the subseque
intervention. a, Macroscopic view of the implanted
toward the patch from the posterior wall. b, Infarcted
ial and epicardial myocytes visualized by anti-slow-
ering the infarction zone (Sham group) evidenced by
e living cardiomyocyte filaments. d, Islet of engrafted
-fast-myosin antibody (600). e, Immunostaining using
B group) the cells are randomly oriented. No skeletal
entiation to myotubes of the grafted cells. f, Immuno-
genic progenitor cells (PU-MyoB) spreading undiffer-after
ning
card
bord
of th
y anti
-Myo
differ
myo
).roliferation of the surviving cells to reverse the initial graft
and Cardiovascular Surgery ● Volume 132, Number 1 129
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1
TXttrition.15 Although cell loss is a multifactorial proce
hysical strain related to the multiple injections is usually
dentified as a contributory factor. This has provided a
ationale for testing myoblast-seeded scaffolds that could
epresent a less invasive and more expeditious means of
elivering the candidate cells to the target scar. A compa-
able approach has been tried by some groups using fibro-
lasts or bone marrow cells bound to different scaffolds,
ainly achieving a benefit through neovascularization.16 –18
eing aware of the properties of myoblasts to restore myo-
ardial function, we transferred this concept to myoblast-
ased scaffolds.
However, very interestingly, we observed that despite
he high number of cells that could be brought using this
echnique (80% of initial cells applied: 3.9  0.5  106
iable cells), we were not able to increase the functional
enefit as compared with the direct injection approach
10%-20% of the initial cells applied survive the injection
rocess). This raises several questions, one being that the
umber of transplanted cells, although probably impor-
ant,19 may not be as critical as initially thought, at 
egarding the contractile function. Consequently, other
echanisms are certainly involved.
The histologic observations that myoblasts bound to
caffolds retained an undifferentiated phenotype and, more
mportant, did not migrate toward the diseased area proba-
ly account for the inability of these “entrapped” cells to
ctively participate in contraction and/or relaxation and
heir resulting failure to elicit a superior functional outcome.
t the same time, these data provide some mechanistic
nsights in that they suggest that the benefits seen in the
U-MyoB group compared with sham or control animals
ere likely related to some paracrine signaling independent
f the intrinsic contractile properties of myoblasts.9,20 –22
icroarray gene studies and subsequent proteomic analy-
es, currently underway in our laboratory, are now trying to
dentify the myoblast-derived factors that may act on an-
iogenesis, extracellular matrix remodeling, apoptosis, or
esident cardiac cell proliferation and account for the ben-
fits of these cells on heart function, even though they
emained epicardially located.
Furthermore, the improved recovery patterns seen in the
yoblast-seeded PU group (PU-MyoB) compared with the
yoblast-free control PU counterparts also suggest that
iologic patches may be more effective than exclusively
ynthetic passive constraint devices for limiting postinfarc-
ion left ventricular remodeling and the ensuing deteriora-
ion of heart function. The observation that directly injected
yoblasts were more effective than myoblasts seeded on
U matrices in preserving postinfarction left ventricular
eometry could be related to the physical properties of our
U scaffold or to the fact that it simply overlaid the scar
rea and was therefore not able to exert the girdling effect
30 The Journal of Thoracic and Cardiovascular Surgery ● Julyt
hat may result from a more complete wrapping of the entire
eft ventricle.
Limitations of this study include the relatively brief
eriod of follow-up that precludes assessing a potential later
yoblast differentiation as well as the lack of identification
f the growth factors/cytokines that may have mediated the
unctional effects of the seeded myoblasts. Furthermore, the
yoblast purity we obtained (about 33%), even if in accor-
ance with others (Leobon and associates11 34%, Az-
rnoush and associates23 38%) remains relatively low. Co-
equently, the real contribution of the myoblasts to the
unctional effect can obviously be questioned. Indeed, the
ffect of a pure fibroblast preparation was not tested in our
tudy. Finally, it also remains to assess whether the in-
ramyocardial injections of chemoattractants like stroma-
erived factor 124 could enhance migration of the super-
ially deposited myoblasts, promote their intramyocardial
ngraftment, and foster cardiac tissue repair.
In conclusion, this study raises a cautionary note about
he putative superiority of scaffold-seeded myoblasts above
he direct injection technique and provides indirect mecha-
istic evidence for the paracrinally mediated effects of these
ells on the postinfarction improvement in functional
utcomes.
Artelon-PU scaffold material was kindly supplied by R&D
epartment of Artimplant AB (Västra Frölunda, Sweden; person
f contact: Ulf Akerblom) with scientific support from Elisabeth
iljensten.
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